Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorodeoxyglucose F18 | 46 | 2024 | 2048 | 5.080 |
Why?
|
Radiopharmaceuticals | 45 | 2024 | 2731 | 3.130 |
Why?
|
Neuroendocrine Tumors | 7 | 2024 | 650 | 2.400 |
Why?
|
Inflammatory Breast Neoplasms | 9 | 2021 | 154 | 2.040 |
Why?
|
Positron-Emission Tomography | 49 | 2024 | 6657 | 1.960 |
Why?
|
Organometallic Compounds | 5 | 2022 | 649 | 1.910 |
Why?
|
Receptors, Peptide | 3 | 2024 | 280 | 1.540 |
Why?
|
Radium | 6 | 2024 | 72 | 1.400 |
Why?
|
Octreotide | 5 | 2024 | 155 | 1.250 |
Why?
|
Dipeptides | 4 | 2023 | 386 | 1.110 |
Why?
|
Lutetium | 3 | 2023 | 38 | 1.090 |
Why?
|
Nuclear Medicine | 8 | 2024 | 258 | 1.070 |
Why?
|
Heterocyclic Compounds, 1-Ring | 3 | 2023 | 68 | 1.060 |
Why?
|
Receptors, Somatostatin | 3 | 2024 | 138 | 1.050 |
Why?
|
Adipose Tissue, Brown | 4 | 2021 | 776 | 1.010 |
Why?
|
Tomography, X-Ray Computed | 30 | 2024 | 20763 | 0.980 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2483 | 0.960 |
Why?
|
Bone Neoplasms | 7 | 2024 | 2562 | 0.950 |
Why?
|
Radioimmunotherapy | 7 | 2013 | 93 | 0.950 |
Why?
|
Hodgkin Disease | 4 | 2022 | 1386 | 0.950 |
Why?
|
Lymphoma | 7 | 2017 | 1907 | 0.930 |
Why?
|
Dihydrotestosterone | 2 | 2023 | 195 | 0.920 |
Why?
|
Alpha Particles | 1 | 2024 | 29 | 0.920 |
Why?
|
Prostatic Neoplasms | 9 | 2024 | 11206 | 0.690 |
Why?
|
Cyclobutanes | 1 | 2020 | 57 | 0.670 |
Why?
|
Radioisotopes | 7 | 2024 | 516 | 0.670 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 598 | 0.670 |
Why?
|
Carboxylic Acids | 1 | 2020 | 91 | 0.670 |
Why?
|
Ribs | 1 | 2021 | 261 | 0.660 |
Why?
|
Breast Neoplasms | 12 | 2024 | 21157 | 0.650 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 1427 | 0.640 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 631 | 0.640 |
Why?
|
Receptors, Androgen | 2 | 2023 | 1084 | 0.610 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1905 | 0.590 |
Why?
|
Diagnostic Imaging | 5 | 2017 | 3543 | 0.540 |
Why?
|
Carcinoma, Lobular | 1 | 2020 | 480 | 0.510 |
Why?
|
Biological Products | 2 | 2024 | 937 | 0.500 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2024 | 9425 | 0.490 |
Why?
|
Molecular Imaging | 2 | 2012 | 825 | 0.480 |
Why?
|
Patient Care Planning | 1 | 2020 | 904 | 0.470 |
Why?
|
Radiometry | 6 | 2023 | 816 | 0.460 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 1602 | 0.450 |
Why?
|
Humans | 123 | 2024 | 768369 | 0.430 |
Why?
|
Salvage Therapy | 3 | 2024 | 1277 | 0.420 |
Why?
|
Neoplasms | 13 | 2024 | 22389 | 0.420 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1092 | 0.410 |
Why?
|
Radiotherapy | 3 | 2018 | 1510 | 0.410 |
Why?
|
Blood Glucose | 3 | 2018 | 6429 | 0.390 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4931 | 0.380 |
Why?
|
Parathyroid Neoplasms | 2 | 2010 | 244 | 0.380 |
Why?
|
Neoplasm Staging | 11 | 2024 | 11249 | 0.370 |
Why?
|
Radionuclide Imaging | 7 | 2023 | 1998 | 0.370 |
Why?
|
Colon | 1 | 2019 | 1804 | 0.370 |
Why?
|
Carcinoma | 5 | 2021 | 2341 | 0.350 |
Why?
|
Head and Neck Neoplasms | 3 | 2022 | 2915 | 0.340 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 9261 | 0.330 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2009 | 1142 | 0.320 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 4083 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5708 | 0.310 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 539 | 0.310 |
Why?
|
Prostate | 4 | 2024 | 1781 | 0.300 |
Why?
|
Transplantation, Autologous | 4 | 2023 | 2126 | 0.300 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1382 | 0.300 |
Why?
|
Hyperparathyroidism | 1 | 2008 | 339 | 0.280 |
Why?
|
Neck Muscles | 1 | 2007 | 100 | 0.280 |
Why?
|
Retrospective Studies | 30 | 2024 | 81835 | 0.280 |
Why?
|
Middle Aged | 51 | 2024 | 223406 | 0.270 |
Why?
|
Diagnosis, Differential | 9 | 2020 | 13025 | 0.270 |
Why?
|
Immunotherapy | 3 | 2022 | 4728 | 0.270 |
Why?
|
Male | 55 | 2024 | 364761 | 0.270 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4299 | 0.260 |
Why?
|
Female | 58 | 2024 | 396926 | 0.260 |
Why?
|
Cell Proliferation | 2 | 2021 | 10490 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 11844 | 0.250 |
Why?
|
Aged | 44 | 2024 | 171514 | 0.250 |
Why?
|
Intercostal Muscles | 1 | 2004 | 26 | 0.240 |
Why?
|
Lymphatic Diseases | 1 | 2006 | 320 | 0.230 |
Why?
|
Tissue Distribution | 5 | 2019 | 2298 | 0.230 |
Why?
|
Adult | 40 | 2024 | 223528 | 0.230 |
Why?
|
Prostatectomy | 4 | 2024 | 1840 | 0.220 |
Why?
|
Treatment Outcome | 20 | 2024 | 65408 | 0.220 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 631 | 0.220 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7449 | 0.210 |
Why?
|
Neck | 1 | 2007 | 736 | 0.210 |
Why?
|
Adenoma | 2 | 2010 | 2163 | 0.200 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2930 | 0.200 |
Why?
|
Adrenocortical Carcinoma | 1 | 2022 | 88 | 0.190 |
Why?
|
Subtraction Technique | 1 | 2004 | 519 | 0.190 |
Why?
|
Head | 1 | 2007 | 927 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2017 | 1794 | 0.190 |
Why?
|
Taxoids | 2 | 2022 | 669 | 0.190 |
Why?
|
Aged, 80 and over | 22 | 2024 | 59679 | 0.190 |
Why?
|
Mitotic Index | 1 | 2021 | 164 | 0.190 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2022 | 161 | 0.180 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 945 | 0.180 |
Why?
|
Paraganglioma | 1 | 2022 | 143 | 0.180 |
Why?
|
Prognosis | 7 | 2022 | 30031 | 0.180 |
Why?
|
Gastric Emptying | 1 | 2022 | 246 | 0.170 |
Why?
|
Mastectomy | 4 | 2021 | 1852 | 0.170 |
Why?
|
Pheochromocytoma | 1 | 2022 | 328 | 0.170 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 637 | 0.170 |
Why?
|
Education, Medical | 1 | 2012 | 1742 | 0.170 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1145 | 0.170 |
Why?
|
Fluorine Radioisotopes | 2 | 2021 | 425 | 0.170 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 1680 | 0.170 |
Why?
|
Internship and Residency | 3 | 2022 | 5952 | 0.160 |
Why?
|
Biological Transport | 2 | 2021 | 2090 | 0.160 |
Why?
|
Cholecystokinin | 1 | 2019 | 115 | 0.160 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2019 | 136 | 0.160 |
Why?
|
Survival Analysis | 4 | 2021 | 10127 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2018 | 3550 | 0.160 |
Why?
|
Contrast Media | 2 | 2024 | 5337 | 0.160 |
Why?
|
Body Weight | 1 | 2009 | 4630 | 0.150 |
Why?
|
Thyroid Neoplasms | 2 | 2009 | 2360 | 0.150 |
Why?
|
Neoplasm, Residual | 5 | 2023 | 1014 | 0.150 |
Why?
|
Radiotherapy Dosage | 5 | 2018 | 2925 | 0.150 |
Why?
|
Gallbladder | 1 | 2019 | 308 | 0.150 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2017 | 959 | 0.140 |
Why?
|
Parathyroid Glands | 2 | 2010 | 522 | 0.140 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2020 | 238 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 882 | 0.140 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2896 | 0.140 |
Why?
|
Crohn Disease | 1 | 2009 | 2292 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2022 | 736 | 0.140 |
Why?
|
Whole-Body Irradiation | 1 | 2017 | 434 | 0.130 |
Why?
|
Hepatitis C | 1 | 2006 | 1594 | 0.130 |
Why?
|
Axilla | 1 | 2018 | 629 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 423 | 0.130 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13709 | 0.130 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 57 | 0.130 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2586 | 0.130 |
Why?
|
Intestinal Neoplasms | 2 | 2018 | 317 | 0.130 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 344 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1376 | 0.120 |
Why?
|
Artifacts | 2 | 2018 | 1927 | 0.120 |
Why?
|
Beta Particles | 1 | 2015 | 51 | 0.120 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2009 | 679 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1505 | 0.120 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2243 | 0.120 |
Why?
|
Sensitivity and Specificity | 7 | 2010 | 14725 | 0.110 |
Why?
|
Genes, Retinoblastoma | 1 | 2014 | 125 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 876 | 0.110 |
Why?
|
Remission Induction | 2 | 2017 | 2408 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10358 | 0.110 |
Why?
|
Glucose | 2 | 2022 | 4355 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 905 | 0.110 |
Why?
|
Pilot Projects | 3 | 2021 | 8730 | 0.110 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8559 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1276 | 0.100 |
Why?
|
Vascular Neoplasms | 1 | 2014 | 167 | 0.100 |
Why?
|
Cerebral Hemorrhage | 1 | 2023 | 2665 | 0.100 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 460 | 0.100 |
Why?
|
Medical Oncology | 1 | 2024 | 2347 | 0.100 |
Why?
|
Acute Kidney Injury | 1 | 2024 | 1943 | 0.100 |
Why?
|
Radiology Department, Hospital | 1 | 2016 | 409 | 0.100 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 241 | 0.100 |
Why?
|
Sirolimus | 2 | 2009 | 1542 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39429 | 0.090 |
Why?
|
Observer Variation | 2 | 2024 | 2622 | 0.090 |
Why?
|
Societies, Medical | 3 | 2024 | 3954 | 0.090 |
Why?
|
Radiation Dosage | 2 | 2017 | 1974 | 0.090 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 463 | 0.090 |
Why?
|
Bone Marrow | 3 | 2010 | 2929 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4077 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3697 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 595 | 0.080 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 425 | 0.080 |
Why?
|
Bone Marrow Neoplasms | 1 | 2010 | 101 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3433 | 0.080 |
Why?
|
Mammaplasty | 1 | 2019 | 1262 | 0.080 |
Why?
|
Oxygen Radioisotopes | 1 | 2008 | 75 | 0.080 |
Why?
|
Cold Temperature | 2 | 2010 | 786 | 0.080 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2008 | 53 | 0.080 |
Why?
|
Rats, Inbred Lew | 2 | 2010 | 1165 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 184 | 0.080 |
Why?
|
Ovarian Neoplasms | 2 | 2021 | 4906 | 0.080 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 331 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2339 | 0.080 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 3047 | 0.080 |
Why?
|
Bronchial Neoplasms | 1 | 2008 | 111 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 36840 | 0.070 |
Why?
|
Parathyroidectomy | 1 | 2010 | 244 | 0.070 |
Why?
|
Molecular Mimicry | 1 | 2008 | 213 | 0.070 |
Why?
|
Benzamides | 1 | 2013 | 1381 | 0.070 |
Why?
|
Smoking | 1 | 2004 | 9099 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 952 | 0.070 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2010 | 164 | 0.070 |
Why?
|
Hypertrophy | 1 | 2009 | 562 | 0.070 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2007 | 53 | 0.070 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 617 | 0.070 |
Why?
|
Survival Rate | 5 | 2017 | 12875 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1600 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3520 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2601 | 0.070 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6856 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2010 | 499 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9642 | 0.070 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 413 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14766 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5891 | 0.070 |
Why?
|
Filgrastim | 1 | 2006 | 132 | 0.070 |
Why?
|
Mastectomy, Modified Radical | 2 | 2017 | 62 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2013 | 1205 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2009 | 1103 | 0.060 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 363 | 0.060 |
Why?
|
Hormones | 2 | 2022 | 870 | 0.060 |
Why?
|
Laboratories | 1 | 2009 | 463 | 0.060 |
Why?
|
Pyrimidines | 2 | 2018 | 3050 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2785 | 0.060 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2009 | 325 | 0.060 |
Why?
|
Thyrotropin | 1 | 2009 | 834 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2006 | 642 | 0.060 |
Why?
|
Arteries | 1 | 2010 | 1126 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6537 | 0.060 |
Why?
|
Muscles | 1 | 2009 | 1582 | 0.060 |
Why?
|
Young Adult | 6 | 2017 | 60038 | 0.060 |
Why?
|
Skull | 1 | 2008 | 832 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1527 | 0.060 |
Why?
|
Time Factors | 5 | 2019 | 40271 | 0.060 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2024 | 89 | 0.060 |
Why?
|
Bleomycin | 2 | 2017 | 495 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12096 | 0.060 |
Why?
|
Reproducibility of Results | 5 | 2024 | 20232 | 0.050 |
Why?
|
Vinblastine | 2 | 2017 | 488 | 0.050 |
Why?
|
Thrombocytopenia | 2 | 2010 | 1183 | 0.050 |
Why?
|
Pelvic Neoplasms | 1 | 2005 | 250 | 0.050 |
Why?
|
Doxorubicin | 3 | 2017 | 2229 | 0.050 |
Why?
|
Carcinoma, Renal Cell | 1 | 2018 | 3198 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2546 | 0.050 |
Why?
|
Mammography | 1 | 2013 | 2436 | 0.050 |
Why?
|
Kinetics | 3 | 2021 | 6347 | 0.050 |
Why?
|
Hernia, Inguinal | 1 | 2005 | 225 | 0.050 |
Why?
|
Edetic Acid | 1 | 2023 | 278 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2526 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2006 | 518 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 1005 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4861 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2023 | 195 | 0.050 |
Why?
|
Dacarbazine | 2 | 2017 | 560 | 0.050 |
Why?
|
Toes | 1 | 2023 | 209 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1608 | 0.050 |
Why?
|
Tamoxifen | 1 | 2006 | 968 | 0.050 |
Why?
|
Thoracic Vertebrae | 1 | 2006 | 613 | 0.050 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 148 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2024 | 437 | 0.050 |
Why?
|
United States | 4 | 2024 | 73120 | 0.050 |
Why?
|
Organ Specificity | 1 | 2006 | 1974 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1339 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1852 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2006 | 1195 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2008 | 6400 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2465 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6527 | 0.040 |
Why?
|
Abdomen | 1 | 2006 | 1136 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2009 | 2528 | 0.040 |
Why?
|
Spleen | 1 | 2006 | 2298 | 0.040 |
Why?
|
Antigens, Surface | 1 | 2024 | 1615 | 0.040 |
Why?
|
Melanoma | 1 | 2018 | 5740 | 0.040 |
Why?
|
Technetium Tc 99m Lidofenin | 1 | 2019 | 3 | 0.040 |
Why?
|
Forecasting | 1 | 2009 | 2950 | 0.040 |
Why?
|
Spinal Neoplasms | 1 | 2006 | 715 | 0.040 |
Why?
|
Risk Factors | 3 | 2018 | 74915 | 0.040 |
Why?
|
Radiation Tolerance | 1 | 2021 | 478 | 0.040 |
Why?
|
Monte Carlo Method | 3 | 2010 | 1262 | 0.040 |
Why?
|
Radioactive Tracers | 1 | 2019 | 68 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2228 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2224 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 695 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4941 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12561 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8051 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 54913 | 0.040 |
Why?
|
Consent Forms | 1 | 2018 | 55 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1179 | 0.040 |
Why?
|
Reoperation | 1 | 2008 | 4342 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 697 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2006 | 1536 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2655 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3439 | 0.040 |
Why?
|
Oligopeptides | 1 | 2023 | 1193 | 0.040 |
Why?
|
Disease Progression | 4 | 2016 | 13643 | 0.030 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 890 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2023 | 9066 | 0.030 |
Why?
|
Brain Neoplasms | 2 | 2015 | 9177 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 306 | 0.030 |
Why?
|
Tissue Extracts | 1 | 2016 | 139 | 0.030 |
Why?
|
Recurrence | 1 | 2008 | 8510 | 0.030 |
Why?
|
Career Choice | 1 | 2022 | 769 | 0.030 |
Why?
|
Eating | 1 | 2022 | 1538 | 0.030 |
Why?
|
Patient Selection | 2 | 2023 | 4266 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2544 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2564 | 0.030 |
Why?
|
Acute Disease | 1 | 2006 | 7245 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2008 | 3407 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 286 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4362 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 583 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 41782 | 0.030 |
Why?
|
Rats | 2 | 2010 | 23839 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 682 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4213 | 0.030 |
Why?
|
Radiology | 1 | 2007 | 2118 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 969 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 546 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2023 | 3472 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10784 | 0.020 |
Why?
|
Animals | 4 | 2015 | 169424 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 9505 | 0.020 |
Why?
|
Body Mass Index | 1 | 2009 | 13030 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6995 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 582 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5887 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6979 | 0.020 |
Why?
|
B-Lymphocyte Subsets | 1 | 2012 | 240 | 0.020 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 168 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4613 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 305 | 0.020 |
Why?
|
Yttrium Radioisotopes | 1 | 2010 | 114 | 0.020 |
Why?
|
Inflammation | 1 | 2009 | 10863 | 0.020 |
Why?
|
Vincristine | 1 | 2012 | 1039 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6816 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2009 | 113 | 0.020 |
Why?
|
Tonsillar Neoplasms | 1 | 2009 | 50 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1622 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 408 | 0.020 |
Why?
|
Absorption | 1 | 2009 | 243 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 15459 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 186 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 643 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1988 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1672 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 786 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 89163 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1484 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2009 | 186 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 840 | 0.020 |
Why?
|
Prednisone | 1 | 2012 | 1568 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 6217 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10269 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2010 | 1604 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 892 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 1081 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4545 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2008 | 666 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 1656 | 0.020 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 616 | 0.020 |
Why?
|
Spinal Cord | 1 | 2013 | 1814 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1722 | 0.020 |
Why?
|
Models, Statistical | 2 | 2010 | 5103 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2008 | 1377 | 0.010 |
Why?
|
Fatigue | 1 | 2012 | 1556 | 0.010 |
Why?
|
Thorax | 1 | 2007 | 559 | 0.010 |
Why?
|
Quinazolines | 1 | 2010 | 1376 | 0.010 |
Why?
|
Internationality | 1 | 2009 | 1007 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1207 | 0.010 |
Why?
|
Bone and Bones | 1 | 2013 | 2589 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2009 | 915 | 0.010 |
Why?
|
World Health Organization | 1 | 2009 | 1327 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9359 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3635 | 0.010 |
Why?
|
Water | 1 | 2008 | 1421 | 0.010 |
Why?
|
Lung Diseases | 1 | 2012 | 1926 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1898 | 0.010 |
Why?
|
Temporal Lobe | 1 | 2008 | 1728 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3619 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5880 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5443 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3463 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11139 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2004 | 13589 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2009 | 2067 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1444 | 0.010 |
Why?
|
Child | 1 | 2007 | 80856 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2257 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8331 | 0.010 |
Why?
|
Neutrophils | 1 | 2010 | 3790 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5193 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3329 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30235 | 0.010 |
Why?
|
Software | 1 | 2010 | 4465 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5342 | 0.010 |
Why?
|
Lung | 1 | 2013 | 10090 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 13497 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6278 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 6607 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 17149 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 14157 | 0.010 |
Why?
|
Brain | 1 | 2013 | 27439 | 0.000 |
Why?
|
Mice | 1 | 2009 | 82051 | 0.000 |
Why?
|